Federal regulators are looking into whether a hostile offer jointly pursued by Valeant Pharmaceuticals International Inc and activist investor William Ackman to acquire Allergan Inc violates securities laws according to people familiar with the matter The Securities and Exchange Commission civil probe is focused on potential breaches of insidertrading laws one of the people said The inquiry is at a relatively early stage and may not lead to any enforcement action the person added